Cassava Sciences Inc SAVA announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus placebo ...

Cassava Sciences Inc. (NASDAQ:SAVA) on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. REFOCUS-ALZ randomized approximately ...

A struggling biotech stock is on the move today on news of a trial extension. Indeed, Cassava Sciences (NASDAQ:SAVA) has announced that it will be extending trials of simufilam — its lead Alzheimer’s ...

Oral Simufilam Continues to be Safe, Well Tolerated. AUSTIN, Texas, July 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced top-line clinical ...

Cassava Sciences (NASDAQ:SAVA) took a big hit last week on July 29 right after it released absolutely excellent results from its Alzheimer’s drug, Simufilam. As a result, SAVA stock looks deeply ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent manner Results confirm and extend ...

No significant reduction in cognitive or functional decline was observed with simufilam compared with placebo. A phase 3 trial evaluating simufilam for the treatment of Alzheimer disease (AD) did not ...

Please provide your email address to receive an email when new articles are posted on . Topline results from the phase 3 ReThink-ALZ study of simufilam in mild to moderate Alzheimer’s disease showed ...

An interim analysis of the open-label study of simufilam, Cassava Sciences Inc., of Austin, Texas, showed six months’ treatment with the oral, small molecule improved cognition and behavior scores in ...

AUSTIN, Texas, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today it has initiated an initial Phase 3 ...